Tumoral CD 105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma A Saroufim, Y Messai, M Hasmim, N Rioux, R Iacovelli, G Verhoest, K Bensalah, J-J Patard, L Albiges, B Azzarone, et al.

[1]  J. Patard,et al.  Metabolism of kidney cancer: from the lab to clinical practice. , 2013, European urology.

[2]  David S Mendelson,et al.  A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[3]  C. Streutker,et al.  Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. , 2012, Human pathology.

[4]  C. Sternberg,et al.  Targeted therapies for renal cell carcinoma: review of adverse event management strategies. , 2012, Journal of the National Cancer Institute.

[5]  B. Rini,et al.  Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.

[6]  G. Camussi,et al.  Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. , 2011, Cancer research.

[7]  J. Patard,et al.  Prognostic factors in renal cell carcinoma , 2010, World Journal of Urology.

[8]  C. Heeschen,et al.  Cancer stem cells in solid tumors. , 2010, Seminars in cancer biology.

[9]  G. Camussi,et al.  Identification of a tumor‐initiating stem cell population in human renal carcinomas , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  L. Ellis,et al.  Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy , 2008, Clinical Cancer Research.

[11]  O. Tokunaga,et al.  Organ‐specific endoglin (CD105) expression in the angiogenesis of human cancers , 2006, Pathology international.

[12]  K. Grankvist,et al.  Endoglin (CD105) expression in human renal cell carcinoma , 2006, BJU international.

[13]  F. McGovern,et al.  Renal-cell carcinoma. , 2005, The New England journal of medicine.

[14]  R. Montironi,et al.  Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. , 2005, The Journal of urology.

[15]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[16]  Shant Kumar,et al.  CD105 is important for angiogenesis: evidence and potential applications , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  N. Kawata,et al.  Histopathological analysis of angiogenic factors in renal cell carcinoma , 2003, International journal of urology : official journal of the Japanese Urological Association.

[18]  P. Stattin,et al.  Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer , 2002, The Prostate.

[19]  B. Seon,et al.  Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. , 2001, Cancer research.

[20]  Shant Kumar,et al.  Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer , 2000, International journal of cancer.

[21]  R. Derynck,et al.  TGF-beta receptor signaling. , 1997, Biochimica et biophysica acta.

[22]  B. Delahunt,et al.  Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. , 1997, British journal of urology.

[23]  M. Barcos,et al.  Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[25]  J. Wang,et al.  CD 105 and angiogenesis. , 1996, The Journal of pathology.

[26]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[27]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[28]  M. Letarte,et al.  Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. , 1990, The Journal of biological chemistry.

[29]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.